Hipolin Limited , a detergent manufacturing company, has announced its financial results for the second quarter of the fiscal year 2026, ending September 30, 2025. The company's performance indicates continued challenges in its operations.

Key Financial Highlights

Revenue and Profitability

Hipolin Limited reported a revenue from operations of Rs 318.08 lacs for the quarter, marking a significant decrease from Rs 552.36 lacs in the corresponding quarter of the previous fiscal year. The total income for Q2 FY2026 stood at Rs 323.15 lacs, compared to Rs 563.20 lacs in Q2 FY2025.

Expenses and Net Loss

The company's total expenses for the quarter amounted to Rs 322.69 lacs, lower than the Rs 601.64 lacs reported in the same quarter last year. Despite the reduction in expenses, Hipolin Limited posted a net loss of Rs 73.12 lacs for Q2 FY2026, which is higher than the net loss of Rs 38.44 lacs recorded in Q2 FY2025.

Operational Performance

The increased net loss, despite lower expenses, suggests that Hipolin Limited may be facing challenges in its core operations. The company's primary business remains the manufacturing of detergent powder and cake, which falls within a single business segment.

Board Approval and Audit Review

The unaudited financial results were approved by Hipolin Limited's Board of Directors in a meeting held on November 14, 2025. The company's statutory auditors have conducted a limited review of these results and have issued an unmodified review report.

Consolidated Results

On a consolidated basis, which includes the results of its subsidiary Jayantilal Bhogilal Chemicals Private Limited, Hipolin Limited reported similar figures, with a net loss of Rs 73.06 lacs for the quarter.

Balance Sheet Position

As of September 30, 2025, Hipolin Limited's total assets stood at Rs 986.57 lacs, down from Rs 1,297.64 lacs at the end of the previous fiscal year. The company's equity share capital remained unchanged at Rs 313.13 lacs.

Cash Flow

The company's cash and cash equivalents decreased from Rs 28.11 lacs at the beginning of the period to Rs 1.82 lacs by the end of Q2 FY2026, indicating a tightening of liquidity.

Investors and stakeholders will be watching closely to see how Hipolin Limited addresses its ongoing losses and improves its operational performance in the coming quarters.

Hipolin Limited , a company listed on the Bombay Stock Exchange (BSE: 530853), has reported its financial results for the fiscal year ended March 31, 2025. The company's Board of Directors approved both standalone and consolidated audited financial statements in a meeting held on May 29, 2025.

Financial Performance

The company's financial performance for FY 2025 shows a substantial increase in net loss and a slight improvement in total income. Here's a breakdown of the key financial metrics:

Key Highlights

1. Deepening Losses: Hipolin Limited's consolidated net loss widened significantly, increasing by 270% year-over-year.

2. Revenue Growth: Despite the increased loss, the company managed to grow its total income by 8.5% compared to the previous year.

3. Rising Expenses: Total expenditure saw a notable increase of 19.5%, outpacing the growth in income.

4. Negative EPS: The company's earnings per share deteriorated from -₹2.83 to -₹10.47, reflecting the impact of the increased net loss.

5. Subsidiary Inclusion: The consolidated financial statements include the results of Jayantilal Bhogilal Chemicals Private Limited, a wholly-owned subsidiary of Hipolin Limited.

6. Share Capital: The paid-up equity share capital remained at ₹313.13 crore, with shares having a face value of ₹10 each.

Board Meeting Details

As per the company's filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors convened on May 29, 2025, to approve these financial results. The meeting, which started at 7:00 PM and concluded at 10:00 PM, also included discussions on other business transactions.

The financial results were accompanied by a Limited Review Report from the company's Statutory Auditor, adding credibility to the reported figures.

While Hipolin Limited has shown some improvement in its top-line performance, the significant increase in net loss and expenditure raises concerns about the company's financial health and operational efficiency.